calamenene has been researched along with Multiple Myeloma in 1 studies
*Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Chiang, SY; Chung, WS; Jang, HJ; Jung, SH; Kim, JS; Kim, SH; Kim, SM; Na, YS; Nam, D; Shim, BS; Song, J | 1 |
1 other study(ies) available for calamenene and Multiple Myeloma
| Article | Year |
|---|---|
8-hydrocalamenene, derived from Reynoutria elliptica, suppresses constitutive STAT3 activation, inhibiting proliferation and enhancing chemosensitization of human multiple myeloma cells.
Topics: Antineoplastic Agents, Phytogenic; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Humans; Janus Kinase 2; Multiple Myeloma; Plant Extracts; Polycyclic Sesquiterpenes; Polygonum; Proto-Oncogene Proteins c-bcl-2; STAT3 Transcription Factor; Terpenes | 2014 |